Published in Antimicrob Agents Chemother on November 01, 1992
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother (2001) 1.10
Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis. Ther Adv Respir Dis (2012) 0.76
Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs. AAPS PharmSciTech (2014) 0.76
Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med (1979) 3.54
GASTRIC SECRETION IN FEVER AND INFECTIOUS DISEASES. J Clin Invest (1933) 1.97
Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med (1984) 1.81
Transintestinal elimination of ciprofloxacin. Chemotherapy (1990) 1.36
Tissue penetration and metabolism of ciprofloxacin. Am J Med (1987) 1.30
Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis (1975) 1.22
Pharmacokinetics and temperature. J Pharm Sci (1974) 1.20
The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. J Pediatr (1962) 1.14
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother (1986) 1.11
Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis (1977) 1.10
Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun (1986) 1.09
Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics (1975) 1.09
Factors affecting bile flow in the rabbit and rat. Am J Physiol (1954) 1.05
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother (1986) 1.04
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet (1987) 1.02
Theophylline disposition in cystic fibrosis. Am Rev Respir Dis (1983) 1.01
Renal function in cystic fibrosis with special reference to the renal sodium handling. Acta Paediatr Scand (1982) 0.98
An overview of the pharmacology of intravenously administered ciprofloxacin. Am J Med (1987) 0.97
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med (1987) 0.97
Premature senescence in cultured skin fibroblasts from subjects with cystic fibrosis. Science (1979) 0.95
Bioavailability of oral antibiotics in cystic fibrosis. Monogr Paediatr (1979) 0.94
Iron absorption and pyrexia. Lancet (1971) 0.93
Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis. Clin Pharmacol Ther (1988) 0.91
Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother (1987) 0.91
Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother (1989) 0.90
Aminoglycoside clearance in patients with cystic fibrosis. J Pediatr (1979) 0.90
Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. Eur J Clin Microbiol Infect Dis (1989) 0.89
Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin Pharmacokinet (1988) 0.88
Advancing age and acute infection influence the kinetics of ceftazidime. Scand J Infect Dis (1989) 0.88
High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients. Infection (1987) 0.88
Pharmacokinetics of netilmicin in children with and without cystic fibrosis. Antimicrob Agents Chemother (1981) 0.87
Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. J Pediatr (1985) 0.86
Decreased renal clearance of sodium in cystic fibrosis. Acta Paediatr Scand (1991) 0.85
Pharmacokinetics of cephalosporins in normal and septicemic rabbits. Antimicrob Agents Chemother (1985) 0.85
Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. Am J Med (1987) 0.84
Influence of endotoxin on the distribution of cephalosporins in rabbits. J Antimicrob Chemother (1986) 0.83
Cephalexin pharmacokinetics in patients with cystic fibrosis. Dev Pharmacol Ther (1984) 0.82
Effect on renal function of essential fatty acid supplementation in cystic fibrosis. J Pediatr (1989) 0.79
The influence of pyrogen induced fever on absorption of sulpha drugs. Vet Rec (1976) 0.78
Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis. Clin Pharmacokinet (1990) 0.78
Assay of ciprofloxacin and norfloxacin in serum and urine by high-performance liquid chromatography. J Chromatogr (1987) 0.77
Renal function in rats with essential fatty acid deficiency. Clin Sci (Lond) (1990) 0.77
Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scand J Infect Dis Suppl (1989) 0.77
Changes of pharmacokinetics of trimethoprim after pretreatment with streptococcal peptidoglycan. Eur J Drug Metab Pharmacokinet (1986) 0.76
Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis. J Antimicrob Chemother (1989) 0.76
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA (1995) 4.88
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med (1995) 4.71
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet (1992) 4.23
Neonatal infections caused by group B streptococci. Scand J Infect Dis (1971) 2.49
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol (1991) 2.46
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost (2006) 2.32
Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax (2007) 2.07
Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax (2004) 1.86
Quantitation of amphotericin B with use of high-pressure liquid chromatography. J Infect Dis (1977) 1.83
Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med (1984) 1.81
Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int (2004) 1.79
Evaluation of a micromethod for determination of antibiotic concentrations in plasma. Eur J Clin Pharmacol (1972) 1.79
Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax (1990) 1.65
Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J (2003) 1.62
Increased bronchial chloride concentration in cystic fibrosis. Scand J Clin Lab Invest (1989) 1.60
Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol (2002) 1.58
Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab (2000) 1.56
Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J (2000) 1.54
Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis. Acta Paediatr Scand (1984) 1.54
Bile acid kinetics and biliary lipid composition in cystic fibrosis. J Hepatol (1996) 1.51
Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol (1987) 1.49
Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol (2001) 1.49
Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. J Antimicrob Chemother (1988) 1.48
European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol (2001) 1.44
Natural history of liver disease in cystic fibrosis. Hepatology (1999) 1.40
Large tunable Rashba spin splitting of a two-dimensional electron gas in Bi2Se3. Phys Rev Lett (2011) 1.37
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol (2000) 1.35
Home intravenous antibiotic treatment of patients with cystic fibrosis. Acta Paediatr (1992) 1.31
Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax (2005) 1.31
Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci U S A (1986) 1.28
Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros (2011) 1.28
Excretion of 3beta-hydroxy-5-cholenoic and 3a-hydroxy-5a-cholanoic acids in urine of infants with biliary atresia. FEBS Lett (1971) 1.26
3-Oxo-delta 4 bile acids in liver disease. Lancet (1988) 1.24
LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis. Br J Cancer (2003) 1.24
Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros (2011) 1.23
Serum gentamicin assay by high-performance liquid chromatography. Clin Chem (1977) 1.22
Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population. Infection (1995) 1.19
Severe hypercholesterolaemia leads to strong Th2 responses to an exogenous antigen. Scand J Immunol (2004) 1.19
Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother (1992) 1.18
One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand (1985) 1.17
Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother (1991) 1.17
Bile acids and pancreatic enzymes during absorption in the newborn. Acta Paediatr Scand (1972) 1.17
Antibodies to staphylococcal teichoic acid and alpha toxin in patients with cystic fibrosis. Acta Paediatr Scand (1986) 1.15
Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother (1992) 1.15
Quantitation of antibiotics using high-pressure liquid chromatography: tetracycline. Antimicrob Agents Chemother (1976) 1.14
Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology (1985) 1.13
Concentrations of ampicillin plus sulbactam in serum and intestinal mucosa and effects on the colonic microflora in patients undergoing colorectal surgery. Eur J Clin Microbiol (1983) 1.13
Rifampicin compared with penicllin in the treatment of gonorrhea. Chemotherapy (1971) 1.11
Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol (1997) 1.11
Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis. Thromb Res (1982) 1.11
Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J (2001) 1.11
Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother (1981) 1.10
Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects. Antimicrob Agents Chemother (1981) 1.10
Morphological findings in the liver of children with cystic fibrosis: a light and electron microscopical study. Hepatology (1986) 1.08
Telomere shortening in renal cell carcinoma. Cancer Res (1994) 1.07
Quantitation of antibiotics by high-pressure liquid chromatography: cephalothin. Antimicrob Agents Chemother (1978) 1.07
Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother (1996) 1.04
Increased frequency of sister chromatid exchanges in cigarette smokers. Hereditas (1978) 1.04
Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. Eur J Clin Nutr (2010) 1.04
Sclerosing cholangitis in cystic fibrosis. Scand J Gastroenterol Suppl (1988) 1.03
Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother (1990) 1.02
Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis. Thorax (1986) 1.02
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia (2011) 1.01
Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother (1983) 1.01
The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med (1985) 1.00
Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev (2002) 1.00
Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer (2003) 1.00
Pharmacokinetics of antimicrobial agents in the elderly. Rev Infect Dis (1987) 0.99
Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia. Eur J Clin Microbiol Infect Dis (1993) 0.99
Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest (1997) 0.98
The renaissance of erythromycin. J Antimicrob Chemother (1986) 0.98
Renal function in cystic fibrosis with special reference to the renal sodium handling. Acta Paediatr Scand (1982) 0.98
Defective bile acid amidation: predicted features of a new inborn error of metabolism. Lancet (1988) 0.97
Delayed puberty in girls with cystic fibrosis despite good clinical status. Pediatrics (1997) 0.97
Microbiological findings in pregnant women with premature rupture of the membranes. Med Microbiol Immunol (1980) 0.97
Pharmacokinetics of ceftazidime in elderly patients and young volunteers. Scand J Infect Dis (1984) 0.97
The influence of the total body exhaust suit on air and wound contamination in elective hip-operations. J Hosp Infect (1983) 0.97
Effect of aztreonam on the colon microflora in patients undergoing colorectal surgery. Infection (1985) 0.97
Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery. Antimicrob Agents Chemother (1982) 0.97
Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer (2013) 0.96
Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand J Clin Lab Invest (1986) 0.96
DNA content in renal cell carcinoma with reference to tumor heterogeneity. Cancer (1985) 0.94
Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother (1992) 0.94
Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology (1998) 0.94
Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer (1999) 0.94
The impact of different antimicrobial agents on the normal gastrointestinal microflora of humans. Rev Infect Dis (1984) 0.93
Urinary tract infection caused by Haemophilus influenzae. A case report. Scand J Urol Nephrol (1988) 0.93